BOSTON--(BUSINESS WIRE)--Cortria Corporation today announced the appointment of Gene Cefali, Pharm.D, Ph.D., as Senior Vice President of Clinical Pharmacology and Formulation Development. Dr. Cefali was previously Vice President of Lead Optimization at Kos Pharmaceuticals (acquired by Abbott Laboratories), where he played a major role in the development of Niaspan®, a novel formulation of niacin and widely prescribed anti-dyslipidemic medicine, as well as three Niaspan® line-extension products. Dr. Cefali is a globally recognized expert in the field of niacin metabolism and pharmacokinetics.
